Dr. Bines has received honoraria from Astra-Zeneca and has acted as either a consultant or in an advisory role for Bristol Myers-Squibb and Astra-Zeneca.
A clinician's perspective
Article first published online: 3 OCT 2008
Copyright © 2008 American Cancer Society
Supplement: Guidelines for International Breast Health and Cancer Control–Implementation
Volume 113, Issue Supplement 8, pages 2353–2358, 15 October 2008
How to Cite
Bines, J. and Eniu, A. (2008), Effective but cost-prohibitive drugs in breast cancer treatment. Cancer, 113: 2353–2358. doi: 10.1002/cncr.23837
The views expressed in this article are the results of independent work and do not represent the views of the authors' institutions.
Complete financial disclosures are presented at the end of this article.
- Issue published online: 3 OCT 2008
- Article first published online: 3 OCT 2008
- Manuscript Accepted: 24 JUN 2008
- Manuscript Received: 10 JUN 2008
This article has been cited by:
- You have free access to this content1
- 2Aqueous extract of Plinia edulis leaves: Antioxidant activity and cytotoxicity to human breast cancer MCF-7 cell line, South African Journal of Botany, 2012, 81, 1, , ,
- 3Breast cancer in Brazil: present status and future goals, The Lancet Oncology, 2012, 13, 3, e95, , , , , ,
- 4Challenges in the management of breast cancer in low- and middle-income countries, Future Oncology, 2012, 8, 12, 1575, ,
- 5Oxidative stress status in metastatic breast cancer patients receiving palliative chemotherapy and its impact on survival rates, Free Radical Research, 2012, 46, 1, 2, , , , , , ,
- 6Does Chemotherapy-Induced Oxidative Stress Improve the Survival Rates of Breast Cancer Patients?, Antioxidants & Redox Signaling, 2011, 15, 4, 903, , , , , , , ,
- 7Gemcitabine and cisplatin salvage regimen in heavily pretreated metastatic breast cancer: a Brazilian experience, Medical Oncology, 2011, 28, S1, 2, , , , ,